2-[4-[(E)-[6-[(2,6-difluorophenyl)methylsulfonyl]-3-oxo-4H-1,4-benzothiazin-2-ylidene]methyl]anilino]acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 2-[4-[(E)-[6-[(2,6-difluorophenyl)methylsulfonyl]-3-oxo-4H-1,4-benzothiazin-2-ylidene]methyl]anilino]acetic acid
• 化学式: C₂₄H₁₈F₂N₂O₅S₂
• 分子量: 516.5
• InChiKey: STURAVBBHYALGE-LSHDLFTRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  146
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• SUBSTITUTED 2-BENZYLIDENE-2H-BENZO[b][1,4]THIAZIN-3(4H)-ONES, DERIVATIVES THEREOF, AND THERAPEUTIC USES THEREOF
  申请人：Reddy E. Premkumar

  公开号：US20140086941A1

  公开（公告）日：2014-03-27

  The present invention relates to compounds according to Formula I: and salts thereof, wherein R 1 , R 2 , R 3 , R 4 , Ar, and n are as defined herein. Methods for preparing compounds of Formula I are also provided. The present invention further includes methods of treating cellular proliferative disorders, such as cancer, with the compounds of Formula I.

  本发明涉及公式I的化合物及其盐，其中R1、R2、R3、R4、Ar和n的定义如本文所述。还提供了制备公式I化合物的方法。本发明还包括使用公式I化合物治疗细胞增殖性疾病，如癌症的方法。
• US9242945B2
  申请人：——

  公开号：US9242945B2

  公开（公告）日：2016-01-26
• [EN] USE OF MULTI-KINASE INHIBITORS TO TREAT RNA VIRUS INFECTIONS<br/>[FR] UTILISATION D'INHIBITEURS MULTIKINASES POUR LE TRAITEMENT D'INFECTIONS PAR VIRUS À ARN
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2021252494A1

  公开（公告）日：2021-12-16

  Provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering a compound of Formula (I), or a salt thereof, or a composition thereof to a subject (e.g., a human subject). Also provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering 108110 or a composition thereof to a subject (e.g., a human subject). In addition, provided herein are methods for treating a virus (e.g,. an RNA virus, such as a SARS-CoV-2) infection or a disease associated therewith (e.g., COVID-19) comprising administering 108600 or a composition thereof to a subject (e.g., a human subject).